Gene deletions in complement factor H related protein gene locus and kidney

transplantation

Running title: CFHR deletions in kidney transplantation

Markkinen Salla[1†], Lokki Inkeri[2,3†], Helanterä Ilkka[4], Ritari Jarmo[1], Partanen Jukka[1], Meri

Seppo[2,5], Hyvärinen Kati[1,*]

[1]Research and Development, Finnish Red Cross Blood Service, Helsinki Finland

[2]Translational Immunology Research Program, Department of Bacteriology and Immunology, Faculty

of Medicine, University of Helsinki, Helsinki, Finland

[3]Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

[4]Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki,

Finland

[5]Diagnostic Center, Helsinki University Hospital, Helsinki, Finland

† These authors contributed equally to this work

[*]Corresponding author

Ilkka Helanterä, MD, PhD, Associate professor

Helsinki University Hospital and University of Helsinki

Transplantation and Liver Surgery

PO Box 340, 00029 HUS, Helsinki, FINLAND

Phone +358 50 4279526

ilkka.helantera@helsinki.fi

ABSTRACT

We recently reported that a homozygous deletion in the complement factor H related

(*CFHR*) protein gene locus predisposed kidney transplant patients to allograft rejection. As

donors carried normal functional genes in the locus, the susceptibility may have resulted

from alloimmune reaction to CFHR proteins. However, we found no evidence for anti-CFH

response in the patients. It is therefore possible that the *CFHR* gene deletions and

consequent protein deficiencies as such affect the rejection risk. Using multiplex ligation-

dependent probe amplification method and genome sequencing, we confirmed that all 15

patients homozygous for rs7542235 GG, a SNP tagging the *CFHR3 1* deletion had deletions

of various sizes that invariably encompassed the whole of *CFHR1* gene. The lack of CFHR1

protein in patient plasma samples was also demonstrated by Western blotting. Plasma

proteomics analyses of biobank samples demonstrated that rs7542235 allele G associates

with significantly changed expression levels of 23 proteins (FDR <0.010). These proteins are

involved in various pathways, including regulation of alloimmune response and their roles in

transplantation outcome merit further studies. Although *CFHR* gene abnormalities have

been associated with kidney diseases, we observed no clinical characteristics shared by or

enriched in patients homozygous for *CFHR1* deletion. This suggests that the deletion as such

was not enriched in a baseline disease in this subgroup with a high risk for rejection. To

conclude, the different deletion types found in patients shared the complete deletion of the

CFHR1 gene pointing to its primary role. Plasma proteomics studies show that deletion-

tagging allele is associated with altered expression of CFH/CFHR proteins.

INTRODUCTION

Prior matching of human leukocyte antigen (HLA), ABO blood group types, and a negative
anti-HLA cross-matching are the golden rule in kidney transplantation. Regardless, some of
the patients still experience complications after kidney transplantation. In search of novel
histocompatibility factors, a study by Steers *et al.*(1) reported that a homozygous gene
deletion of *LIMS1*, and our previous study (2) reported that homozygous gene deletion in
the *CFH* locus consisting of genes coding for complement factor H (*CFH*) and CFH related
proteins (*CFHRs*) were associated with acute rejection of the graft. There are a few mutually
non-exclusive mechanistic explanations to these findings. The rejection may be related to
alloimmune response by the patient against the protein missing from the patient but
expressed by the graft, hence, as such not necessarily linked to the function of the protein.
Alternatively, the rejection risk may be related to the function of the protein missing from
the patient. The functional effect can be direct, i.e., a result of the missing protein, or
caused by expression of the missing protein by the transplanted kidney, or it can be related
to complex downstream networks. A deletion of a gene and adjacent DNA segments may
furthermore lead to changes in the expression of some other genes that can be identified,
for example, using quantitative trait loci (QTL) (3–5) approaches. Steers and co-workers,
who reported association between *LIMS1* gene deletion and graft rejection in kidney
transplantation could identify a specific anti-LIMS1 antibody pointing to alloimmune
response against the LIMS1 protein missing from the patient. In our recent study (2), we
could not replicate the *LIMS1* deletion association in the set of 1025 Finnish kidney
transplantation patients and donors, but instead reported an association between *CFHR*
locus deletion and graft rejection. The *CFHR* locus contains genes encoding for *CFH*, a major
regulator of the alternative pathway (AP) of complement activation, and a set of related
genes, *CFHR1–5* (2,6). CFH inhibits AP activation both in body fluids and on cell surfaces. It
binds to C3b, which has become bound to self surfaces, where it inhibits local complement
activation. In contrast, on "foreign" targets, like microbial or virus surfaces binding of CFH to
surface deposited C3b is weak (7–9). The functions of CFHR1–5 proteins are becoming
better understood. As suggested already a long time ago (10) the CFHRs are known to
promote complement activity by competing with the master inhibitor CFH (6). Genetic
variants of *CFH* and *CFHR1–5* have been linked to the pathogenesis of some kidney diseases,

such as C3 glomerulopathy (11), atypical hemolytic uremic syndrome (12,13) and IgA

nephropathy (14). In the present study, we wanted to understand the effects of *CFHR3–1*

gene deletions in detail. We fine-mapped the deletion boundaries using multiple ligation-

dependent probe amplification (MLPA) and whole genome sequencing (WGS). We found

that deletions of various sizes shared a homozygous deletion of *CFHR1* gene. Proteomics of

plasma samples revealed that, in fact, the deletion-tagging allele resulted in plasma protein

level changes of at least 23 proteins. This shortlist merits further studies.

MATERIALS AND METHODS

Study cohort

The present study included 15 patients from the study of Markkinen *et al*. (2), who had

rs7542235 GG-genotype tagging for the homozygous deletion in the *CFHR3–1* locus. The

patients received their first kidney transplantation during 2007–2017 at the Helsinki

University Hospital, Helsinki, Finland. The characteristics of the whole study population

including the 15 patients with homozygous *CFHR3–1*-deletion tagging variant (GG) and 1010

patients with heterozygous (AG) or homozygous non-deletion genotype (AA) are presented

in **Table 1**. In total of 199 (20%) rejections were observed in our study cohort. The primary

outcome for these patients was biopsy-proven acute rejection, including both antibody-

mediated and T-cell-mediated rejections (15). Borderline changes were also included as

rejections. The characteristics of the 15 patients (8 in the rejection-group and 7 in the non-

rejection-group) with *CFHR3–1*-deletion tagging rs7542235 GG-genotype are presented in

Table 2.

DNA samples were extracted from whole blood at the time of histocompatibility testing for

transplantation, and serum samples were collected for complement-dependent cytotoxic

crossmatch to detect alloantibodies before and after transplantation at the Finnish Red

Cross Blood Service, Helsinki, Finland.

The clinical data were extracted from the Finnish Transplant Registry, which is a national

follow-up registry obliged by law (**Table 1**).

Genotyping and imputation

Genotyping and imputation procedures are explained in more detail in Markkinen et al. (2).
Briefly, the genotyping was performed at the Finnish Institute of Molecular Medicine
(FIMM), Helsinki, Finland using Illumina's Infinium Global Screening array-24 v2.0 with multi-
disease drop-in. The genotyped data were imputed with Finnish SISu v3 reference panel
consisting of high-coverage WGS data from THL Biobank cohorts (N=1768) (Pärn et al.
manuscript in preparation). The variants rs7542235 tagging for *CFHR*-deletion was imputed
and had an estimated quality measurement value, INFO-score, of 0.98.

Multiplex ligation-dependent probe amplification

MLPA was performed for 15 homozygous rs7542235 GG patients (eight with rejection,
seven without rejection) to screen the copy number variations in *CFH/CFHR* genomic region.
Additionally, we performed the analysis for control patients including eight individuals with
heterozygous AG-genotype (four with rejection, four without rejection) and eight individuals
with homozygous AA-genotype (four with rejection, four without rejection). The detailed
description of MLPA procedure is provided in the **Supplementary data**.

Whole genome sequencing

WGS was previously performed for three rs7542235 GG patients with rejection. The results
and detailed information about the WGS for these samples are provided in the main text
and supplementary data of our previous publication (2). Here, we sequenced seven more
patients with GG-genotype (five with rejection, two without rejection). Sequencing was
performed at FIMM, Helsinki, Finland, and the samples were sequenced with Illumina's
NovaSeq S4 NS4-300 run. The number of aligned bases for each sample was 20–50 Gb. The
input reads for each sample were around 200–500 million, and the length of reads was 151
base pairs. The coverage depth for the sequenced samples was 7–17x. More detailed
statistics for the WGS run are presented in **Supplementary Table S2**.

Western blot for CFH/CFHR proteins

In total of 15 serum samples from nine rs7542235 GG patients (five with rejection, four

without rejection) were available for western blot analysis of CFH, CFHR1 and CFHR2

expression. From the 15 serum samples, nine were collected before transplantation (pre-tx)

and six were collected after transplantation (post-tx). The detailed methods for western blot

are provided in the **Supplementary data**.

Expression quantitative trait loci (eQTL) analyses

In the eQTL analyses, we used three databases to see the impact of *CFHR3*–1 deletion

tagging variant rs7542235 to gene expression: 1) The FIVEx browser

(https://fivex.sph.umich.edu/) eQTL data from blood vessel and kidney samples from the

EBI eQTL catalogue (4); 2) the eQTLGen Consortium database (https://www.eqtlgen.org/)

including cis-eQTL, trans-eQTL and eQTS (associations between polygenic scores and gene

expression levels) data from 37 datasets (3) from blood samples; and 3) the Human Kidney

eQTL Atlas (https://susztaklab.com/Kidney_eQTL/index.php) including four studies with

total of 686 microdissected human kidney tubule samples (5). Each of these three databases

share data from the Genotype-Tissue Expression Consortium (GTEx). All the results are

included.

Protein quantitative trait loci (pQTL), gene ontology and Reactome analyses

We used Olink (n = 1225) and SomaScan (n = 865) pQTL plasma proteomics data of healthy

blood donors from FinnGen project (https://www.finngen.fi/en) to see whether the

CFHR3⊡1 deletion tagging variant rs7542235 has effect on protein expression. False

detection rate (FDR) of <0.010 were considered statistically significant. The genes with FDR

<0.010 were included in the gene ontology (GO) enrichment analysis

(https://geneontology.org/) for each three aspects of biological process, molecular function

and cellular component, and Reactome pathway database (https://reactome.org/).

Other statistical analyses

Characteristics of patients in **Table 1** and **Table 2** were described by medians and

interquartile ranges (IQRs) or ranges, and frequencies and percentages. The comparison

between the two groups of patients with rs7542235 GG-genotype and patients with AA/AG-

genotype (**Table 1**), and GG-genotype with rejection and GG-genotype without rejection

(**Table 2**) were analyzed using the nonparametric Mann-Whitney U-test for non-normally

distributed data (recipient age, follow-up time, PRA I and II, HLA eplet mismatch, HLA I eplet

mismatch and HLA II eplet mismatch), Pearson's chi-square test for recipient sex, Fisher's

exact test for primary diagnosis, or Student's t-test for normally distributed data (cold

ischemia). The significance of variation of PRA-values in **Table 2** was not analyzed due to the

low frequency count. P-values <0.05 were considered statistically significant.

RESULTS

Characteristics of the study population

We previously reported genetic association between reduced rejection-free survival and

CFHR3□1-deletion tagging variant rs7542235 genotype GG (2). 15 out of 1025 patients were

homozygous for this deletion-tagging variant, 4% belonging to rejection-group and 1% to

non-rejection group.

The characteristics of the study groups are shown in **Table 1** and **Table 2**. In total of 53% of

rs7542235 GG patients had rejection, whereas the percentage among AG/AA patients was

only 19 (P-value <0.001). Also other diagnoses are more common among patients with

AG/AA patients than in the GG genotype group (P-value <0.001). The primary diagnosis of

hydronephrosis with ureteropelvic junction obstruction is significantly different between the

rs7542235 GG and AG/AA patients with P-value of 0.029 (**Table 1**). No significant difference

in characteristics between those with rejection and without rejection among patients with

rs7522235 GG genotype were found (**Table 2**). There was no enrichment of diagnoses

known to be linked to *CFHR* locus.

Multiplex ligation-dependent probe amplification

MLPA confirmed that all 15 rs7542235 GG patients had homozygous deletions of different
sizes at the *CFH/CFHR* locus, three different types are depicted in the **Figure 1**. The shared
feature of all samples was a homozygous deletion of *CFHR1* gene.

As assumed, eight patients with rs7542235 genotype AA had no deletions at the *CFHR* locus,
and eight patients with heterozygous AG genotype carried a heterozygous deletion
encompassing both the *CFHR1* and *CFHR3* genes (**Figure 2**).

Whole genome sequencing

201 WGS (**Figure 3**) confirmed the results of MLPA; all seven rs7542235 GG patients had
202 homozygous deletions of different sizes but they shared the deletion of the *CFHR1* gene
203 (**Supplementary Figure S1**). In addition to homozygous deletions, WGS results confirmed
204 the findings of MLPA results showing that 5 out of 10 patients carried heterozygous
205 deletions (**Figure 3C and D**).

Western blot of CFH/CFHR proteins

208 The western blot run showed that 9/9 of serum samples from individuals with rs7542235
209 GG genotype lacked the CFHR1 protein (**Figure 4**). The results are in line to those obtained
210 from genetic MLPA and WGS analyses. The more detailed description and genotypes for
211 each serum sample is shown in **Table 3**.

Expression quantitative trait loci analyses

To understand whether the gene deletions or the tagging variant rs7542235 regulates the
expression of other genes we screened the eQTL databases for rs7542235. The results are
presented in **Table 4**. When searching for the *CFHR3–1* deletion-tagging variant rs7542235
from the FIVEx database, the allele G was associated with the lower expression levels of

CFHR1, -3, and *-4* genes. All the results from FIVEx were from GTEx study, including data

from blood vessel and kidney samples. Based on the eQTLGen Consortium database

consisting of only blood samples, rs7542235 G was associated merely with the higher

expression level of *CFH*, with a Z-score of 10.05 and P-value of 8.88 x 10^{-24}. When screening

the Human Kidney eQTL Atlas having samples from kidney tubule, we found two statistically

significant associations in genes *CFHR1* and *CFHR3*, with P-values of 2.73 x 10^{-58} and 4.01 x

10^{-10}, respectively. The beta-values for these findings were negative indicating reduced

expression.

Protein quantitative trait loci, gene ontology and Reactome analyses

When analysing the effect of variant rs7542235 allele G on protein expression, in total of 23

proteins were shown to be differentially expressed. The Olink results showed three genes to

be associated with the *CFHR*-deletion tagging variant with FDR <0.010; *CFH, CFHR2* and

CFHR5 (**Table 5**), each of having positive beta-value and thus meaning an increase in

expression. SomaScan data resulted in total of 22 proteins to be differentially expressed

with FDR <0.010. In concordance to Olink results, also SomaScan showed an increase in

expression for *CFH* and *CFHR5*, and as was assumed, the *CFHR3▢1* deletion tagging variant

resulted in decreased expression of *CFHR1* gene. Other differentially expressed genes with

FDR <0.010 included, e.g., prolactin receptor (*PRLR*) with decreasing expression levels and

Kirre Like Nephrin Family Adhesion Molecule 1 (*KIRREL1*) with increased expression. In the

GO enrichment analysis of molecular function annotation, four out of 23 genes (*CFH, CFHR1,*

CFHR2 and *CFHR5*) were associated to three functions of complement component C3b

binding, opsonin binding and complement binding with FDRs 8.06 x 10^{-6}, 3.71 x 10^{-5} and 5.34

x 10^{-5}, respectively (**Supplementary table S4**). The Reactome pathway analysis showed that

four out of 23 genes (*CFH, CFHR1, CFHR2* and *CFHR5*) were associated to two pathways;

regulation of complement cascade and complement cascade with FDR 1.00 x 10^{-3} for both

(**Supplementary table S4**).

DISCUSSION

We reported earlier that homozygosity for variant rs7542235 allele G, tagging deletions at

the *CFHR3–1* locus, predisposed patients to kidney allograft rejection. To understand better

the mechanisms behind the association, we here fine-mapped the deletion boundaries and

studied the effects of the gene deletion on protein levels. Our results show that kidney

transplantation patients with GG genotype of deletion-tagging variant rs7542235 have gene

deletions of various sizes and types in the *CFHR* locus. The different deletion types,

however, shared the complete deletion of the *CFHR1* gene pointing to its primary role. The

lack of expressed CFHR1 protein in homozygotes could be confirmed by Western blot

analysis. We also showed by using both eQTL databases and proteomics studies that the

rs7542235 allele G is associated with differences in plasma expression levels of various

proteins, not merely with those encoded by genes at the *CFH/CFHR* locus but others as well.

It is of note that the patients having the homozygous *CFHR1* deletion did not share any

particular type of kidney disease. This is understandable, because e.g., C3 glomerulopathy or

CFHR5 nephropathy are known to be associated with an increased rather than decreased

activity of the CFHR proteins. The increased activity is assumed to be due to a tendency to

make dimers that more efficiently compete with CFH. Only an autoimmune form of

haemolytic uremic syndrome, with autoantibodies against CFH, is linked to *CFHR3–1*

deficiency. The spectrum of kidney diseases in patients with homozygous *CFHR1* deletion

was typical to adults receiving a kidney transplant in Finland. It did not involve complement-

mediated diseases.

As mentioned above, a deletion in the *CFHR3–1* locus may promote formation of anti-CFH

antibodies (13,16). Our previous results showed that there were no *de novo* anti-CFH

antibodies detected from serum samples of patients with rs7542235 GG genotype receiving

a graft from a donor of either AG or AA genotype. This suggests that the deletion itself

might not lead to alloimmune response, but could as such explain the association with

rejection or even with the primary diseases of the patients. However, the possibility that

CFHR1 could become the target of cell-mediated immunity has not been excluded.

Sequence and copy number variations in the human *CFH* and *CFHR1–5* gene cluster have

been linked to the kidney disorders such as C3 glomerulopathy (11), and IgA nephropathy

(14). It has been shown that homozygous deletion and deficiency of *CFHR3–1* has a

protective effect in IgA nephropathy (17) and age-related macular disease (AMD) (18). A

hybrid form of the *CFHR3–1* gene has been associated with an increased risk for C3

glomerulopathy (11). This finding indicates that an overactivity of CFHRs is linked to

complement-mediated diseases.

A recent study by Sun *et al*. discovered that a mismatches in *LIMS1* was associated with

death-censored graft loss, and are in expression quantitative trait loci in immune cells for

GCC2, a gene encoding for a protein involved in mannose-6-phosphase receptor recycling

and thus possibly triggering immune responses in the recipient (19). As shown by the eQTL

and pQTL results, it is plausible that the homozygous deletion of *CFHR1* shared by all

patients influences the expression levels of other *CFHR* genes and proteins, and thus could

alter the complement activation. The variant rs7542235 allele G is associated with an

increased protein expression of CFH and decreased expression of CFHR1. While CFH inhibits

complement activation and protects human endothelial cells, CFHR1 has an opposite effect.

CFH is a regulator of the C3 convertase and promotes degradation of C3b and opsonization

of foreign pathogens with iC3b that results in phagocytosis. CFHR1 competes with CFH for

these activities, thereby increasing complement activation. It thus indirectly promotes

C3/C5 convertase activity and complement membrane attack complex assembly. By

inhibiting CFH binding to C3b, CFHR1 promotes C5a formation and consequent

inflammation. In the absence of CFHR1 and CFHR3, local CFH binding and activity would be

increased, resulting in suppression of complement activation, but, on the other hand,

possibly also to an impaired ability to handle injured tissue components.

The capillaries of kidney glomerulus are continually perfused by large volumes of blood, so

the CFH/CFHR complement proteins present in plasma are in direct contact with the

membrane. Due to filtration of water into urine, the concentration of complement proteins

increases as plasma flows through the kidney, thus exposing these glomerular cells and

surfaces to higher concentrations of CFH/CFHR proteins than are found elsewhere in the

body. This could explain why kidney is relatively sensitive to any complement deficiencies.

(20)

Other differentially expressed genes based on proteomics data included *PRLR* and *KIRREL1*.
Prolactin (PRL) is an endocrine hormone that has several physiological effects including
immune system regulation and anti-inflammatory effects. It can trigger the production of
proinflammatory cytokines, also having several anti-inflammatory effects that can reduce
hyperinflammation (21). Prolactin exerts its effects through PRL receptors (PRLRs). *KIRREL1,*
also known as *NEPH1*, is a member of the NEPH protein family and is expressed in kidney
podocytes, cells involved in ensuring size- and charge-selective ultrafiltration. Mutations in
KIRREL1 gene has been linked to hereditary nephrotic syndrome.(22)

In conclusion, we found that patients with rs7542235 GG genotype shared a homozygous
deletion of the *CFHR1* gene. Our plasma proteomics studies also show that deletion-tagging
allele G is associated with altered expression of CFH/CFHR proteins and might thus be
involved in regulation of complement system.

AUTHOR CONTRIBUTIONS STATEMENT

S. Markkinen, J. Partanen and K. Hyvärinen planned the study, interpreted the results and
drafted the manuscript; S. Markkinen, I. Lokki and K. Hyvärinen carried out the genome data
analyses; the MLPA and western blot analyses and interpretation of the results of these
methods were carried out by I. Lokki, S. Markkinen and S. Meri; S. Markkinen executed *in*
silico database searches; J. Ritari combined the pQTL summary statistics; I. Helanterä
provided clinical data and expertise; all authors contributed to the final version of the
manuscript.

CONFLICT OF INTEREST STATEMENT

The authors have no conflicts of interest to declare.

ACKNOWLEDGEMENT

We want to thank Maria Semenova, BSc, for help in collecting the serum samples. We also
want to thank Lauri Snellman, biotechnology engineer, for help in laboratory with MLPA,

and Marcel Messing, PhD, for help with the western blot method. The THL Biobank's SISu v3

Imputation reference panel used for the research were obtained from THL Biobank (study

number: BB2019_12). We thank all study participants for their generous participation in

biobank research. We also want to thank the Sequencing Informatics Team, FIMM Human

Genomics, University of Helsinki for the WGS analyses. We want to acknowledge the

participants and investigators of FinnGen study. The FinnGen project is funded by two

grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following

industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb

(and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp &

Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US

Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, and

Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for

delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL

Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank

Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-

opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank

Tampere (www.tays.fi/en-

US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern

Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-

FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank

(www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank

(www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank

(https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-

birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi

infrastructure (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the

coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed

through the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB.

FUNDING STATEMENT

The study was supported by funding from the Government of Finland VTR funding,

Munuaissäätiö (to S. Markkinen) and Suomen Transplantaatiokirurginen yhdistys ry (to S.

Markkinen), the State Subsidy to Hospitals (TYH2019311 and TYH2022315 to S. Meri),

Helsinki University Hospital Diagnostic Center funds (Y780023006, to S. Meri) and Sigrid

Jusélius Foundation (to S. Meri). FinnGen is funded by two grants from Business Finland

(HUS 4685/31/2016 and UH 4386/31/2016) and twelve industry partners (AbbVie Inc,

AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sarl,

Genentech Inc, GlaxoSmithKline, Janssen Biotech Inc. Maze Therapeutics Inc., Merck Sharp

& Dohme Corp, Novartis, Pfizer Inc., Sanofi). The funders and biobanks had no role in study

design, data collection and analysis, decision to publish, or preparation of the manuscript.

ETHICS STATEMENT

The study conforms to the principles of the Declaration of Helsinki and has been approved

by the ethics committee of Helsinki University Hospital (HUS/1873/2018) and the Finnish

National Supervisory Authority for Welfare and Health (V/9161/2019).

REFERENCES

1.   Steers NJ, Li Y, Drace Z, D'Addario JA, Fischman C, Liu L, et al. Genomic Mismatch at
379   *LIMS1* Locus and Kidney Allograft Rejection. N Engl J Med. 2019;380(20):1918–28.

380   2.   Markkinen S, Helanterä I, Lauronen J, Lempinen M, Partanen J, Hyvärinen K.
381   Mismatches in gene deletions and kidney-related proteins as candidates for
382   histocompatibility factors in kidney transplantation. Kidney Int Reports.
383   2022;7(11):2484–94.

384   3.   Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis-
385   and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that
386   regulate blood gene expression. Nat Genet [Internet]. 2021 Sep 1 [cited 2023 May
387   11];53(9):1300–10. Available from: https://pubmed.ncbi.nlm.nih.gov/34475573/

388   4.   Kwong A, Boughton AP, Wang M, Vandehaar P, Boehnke M, Abecasis G, et al. FIVEx:
389   an interactive eQTL browser across public datasets. Bioinformatics [Internet]. 2022
390   Jan 15 [cited 2023 Oct 27];38(2):559–61. Available from:
391   https://pubmed.ncbi.nlm.nih.gov/34459872/

392   5.   Liu H, Doke T, Guo D, Sheng X, Ma Z, Park J, et al. Epigenomic and transcriptomic
393   analyses define core cell types, genes and targetable mechanisms for kidney disease.
394   Nat Genet [Internet]. 2022 Jul 1 [cited 2023 May 25];54(7):950–62. Available from:
395   https://pubmed.ncbi.nlm.nih.gov/35710981/

396   6.   Lucientes-Continente L, Márquez-Tirado B, Goicoechea de Jorge E. The Factor H
397   protein family: The switchers of the complement alternative pathway. Vol. 313,
398   Immunological Reviews. Immunol Rev; 2023. p. 25–45.

399   7.   Rodríguez De Córdoba S, Esparza-Gordillo J, Goicoechea De Jorge E, Lopez-Trascasa
400   M, Sánchez-Corral P. The human complement factor H: Functional roles, genetic
401   variations and disease associations. Mol Immunol [Internet]. 2004 Jun [cited 2023 Sep
402   20];41(4):355–67. Available from: https://pubmed.ncbi.nlm.nih.gov/15163532/

403   8.   Meri S, Pangburn MK. Discrimination between activators and nonactivators of the
404   alternative pathway of complement: regulation via a sialic acid/polyanion binding site

on factor H. Proc Natl Acad Sci U S A [Internet]. 1990 [cited 2023 Nov

23];87(10):3982–6. Available from: https://pubmed.ncbi.nlm.nih.gov/1692629/

9.   Meri S. Self-nonself discrimination by the complement system. FEBS Lett [Internet].

2016 Aug 1 [cited 2023 Nov 23];590(15):2418–34. Available from:

https://pubmed.ncbi.nlm.nih.gov/27393384/

10. Närkiö-Mäkelä M, Hellwage J, Tahkokallio O, Meri S. Complement-regulator factor H

and related proteins in otitis media with effusion. Clin Immunol [Internet]. 2001 [cited

2023 Nov 23];100(1):118–26. Available from:

https://pubmed.ncbi.nlm.nih.gov/11414752/

11. Malik TH, Lavin PJ, De Jorge EG, Vernon KA, Rose KL, Patel MP, et al. A hybrid CFHR3-1

gene causes familial C3 glomerulopathy. J Am Soc Nephrol [Internet]. 2012 Jul [cited

2023 Nov 2];23(7):1155–60. Available from:

https://pubmed.ncbi.nlm.nih.gov/22626820/

12. Józsi M, Licht C, Strobel S, Zipfel SLH, Richter H, Heinen S, et al. Factor H

autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3

deficiency. Blood [Internet]. 2008 [cited 2023 Nov 9];111(3):1512–4. Available from:

https://pubmed.ncbi.nlm.nih.gov/18006700/

13. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association

of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with

mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic

syndrome. Blood. 2010;115(2):379–87.

14. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study

identifies susceptibility loci for IgA nephropathy. Nat Genet [Internet]. 2011 Feb [cited

2023 Nov 2];43(4):321–9. Available from:

https://pubmed.ncbi.nlm.nih.gov/21399633/

15. Roufosse C, Simmonds N, Clahsen-Van Groningen M, Haas M, Henriksen KJ, Horsfield

C, et al. A 2018 Reference Guide to the Banff Classification of Renal Allograft

Pathology. Transplantation. 2018;102(11):1795–814.

16. Józsi M, Licht C, Strobel S, Zipfel SLH, Richter H, Heinen S, et al. Factor H
autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3
deficiency. Blood. 2008;111(3):1512–4.

17. Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest
[Internet]. 2014 Jun 2 [cited 2023 Nov 9];124(6):2325–32. Available from:
https://pubmed.ncbi.nlm.nih.gov/24892706/

18. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A
common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower
risk of age-related macular degeneration. Nat Genet [Internet]. 2006 Oct [cited 2023
Nov 9];38(10):1173–7. Available from: https://pubmed.ncbi.nlm.nih.gov/16998489/

19. Sun Z, Zhang Z, Banu K, Gibson IW, Colvin RB, Yi Z, et al. Multiscale genetic
architecture of donor-recipient differences reveals intronic LIMS1 mismatches
associated with kidney transplant survival. J Clin Invest [Internet]. 2023 Sep 7 [cited
2023 Oct 25]; Available from: https://pubmed.ncbi.nlm.nih.gov/37676733/

20. Thurman JM, Harrison RA. The susceptibility of the kidney to alternative pathway
activation-A hypothesis. Immunol Rev [Internet]. 2023 Jan 1 [cited 2023 Nov
23];313(1):327–38. Available from: https://pubmed.ncbi.nlm.nih.gov/36369971/

21. Rasmi Y, Jalali L, Khalid S, Shokati A, Tyagi P, Ozturk A, et al. The effects of prolactin on
the immune system, its relationship with the severity of COVID-19, and its potential
immunomodulatory therapeutic effect. Cytokine [Internet]. 2023 Sep 1 [cited 2023
Nov 2];169:156253. Available from: /pmc/articles/PMC10247151/

22. Sellin L, Huber TB, Gerke P, Quack I, Pavenstädt H, Walz G. NEPH1 defines a novel
family of podocin interacting proteins. FASEB J. 2003;17(1):115–7.

Table 1. Characteristics of the study cohort.

Characteristic	All patients, n = 1025	Patients with rs7542235 GG genotype, n = 15	Patients with rs7542235 AA/AG genotype, n = 1010	P-value[a]
Age (median, range)	57 (18–79)	58 (36–74)	57 (18–79)	0.639[c]
Sex, n (%)				1[d]
Male	703 (69)	10 (67)	693 (69)	
Female	322 (31)	5 (33)	317 (31)	
Rejection, n (%)	199 (19)	8 (53)	191 (19)	<0.001[d]
T cell -mediated, n (%)	178 (17)	6 (75)	172 (90)	
Antibody-mediated, n (%)	21 (3)	2 (25)	19 (10)	
Primary diagnosis, n (%)				
Polycystic kidney disease	202 (20)	3 (20)	199 (20)	1[e]
Diabetic nephropathy with type I diabetes	150 (15)	2 (13)	148 (15)	1[e]
IgA nephropathy	106 (10)	2 (13)	104 (10)	0.662[e]
Chronic kidney disease, unspecified	105 (10)	2 (13)	103 (10)	0.660[e]
Glomerular disorder in amyloidosis	6 (1)	1 (7)	5 (1)	0.085[e]
Glomerular disorder in polyarteritis nodosa	4 (0)	1 (7)	3 (0)	0.057[e]
Glomerular disorder in granulomatosis with polyangiitis	10 (1)	1 (7)	9 (1)	0.137[e]
Hydronephrosis with ureteropelvic junction obstruction	2 (0)	1 (7)	1 (0)	0.029[e]
Other chronic kidney disease	22 (2)	1 (7)	21 (2)	0.279[e]
Polycystic kidney disease, unspecified	9 (1)	1 (7)	8 (1)	0.124[e]
Other	409 (40)	0 (0)	409 (40)	<0.001[e]
Median (IQR)				
Death-censored follow-up time, months	37 (18–63)	37 (9–50)	37 (18–63)	0.402[c]
PRA I >0, %[b]	22 (5–55)	52 (20–64)	21 (5–55)	0.290[c]
PRA II >0, %[b]	27 (12–60)	17 (17–58)	27 (12–60)	0.702[c]
Cold ischemia, hours	20 (17–23)	21 (19–22)	20 (17–23)	0.569[e]
HLA eplet mismatch sum, n	27 (19–36)	28 (17–46)	27 (19–36)	0.808[c]
HLA I eplet mismatch sum, n	11 (7–15)	9 (7–13)	11 (7–15)	0.459[c]
HLA II eplet mismatch sum, n	16 (7–24)	22 (8–28)	16 (7–24)	0.388[c]

HLA, human leukocyte antigen; IgA, Immunoglobulin A; IQR, interquartile range; PRA, panel-reactive antibody.
[a]The significance of variation was calculated between rs7542235 GG vs. AG/AA groups.
[b]The medians of PRA values are calculated only from patients with PRA I >0 and PRA II >0.
[c]The Mann–Whitney U-test.
[d]The Pearson chi-square test.
[e]Fisher's exact test.
[f]The Student's t-test.

Table 2. Characteristics of the 15 patients with rs7542235 GG-genotype tagging for homozygous *CFHR3□1*
deletion. Rejection vs. non-rejection group.

Characteristic	Patients with rs7542235 GG genotype, n = 15	Patients with rs7542235 GG genotype with rejection, n = 8	Patients with rs7542235 GG genotype without rejection, n = 7	P-value[a]
Age (median, range)	58 (36-74)	52 (36-73)	61 (53-74)	0.064[c]
Sex, n (%)				0.854[d]
Male	10 (67)	6 (75)	4 (57)	
Female	5 (33)	2 (25)	3 (43)	
Rejection, n (%)	8 (50)	8 (100)	0 (0)	
T cell-mediated, n (%)	6 (38)	6 (75)	0 (0)	
Antibody-mediated, n (%)	2 (12)	2 (25)	0 (0)	
Primary diagnosis, n (%)				
Polycystic kidney disease	3 (20)	0 (0)	3 (43)	0.076[e]
Diabetic nephropathy with type I diabetes	2 (13)	1 (12.5)	1 (14)	1[e]
IgA nephropathy	2 (13)	2 (25)	0 (0)	0.466[e]
Chronic kidney disease, unspecified	2 (13)	2 (25)	0 (0)	0.466[e]
Glomerular disorder in amyloidosis	1 (7)	1 (12.5)	0 (0)	1[e]
Glomerular disorder in polyarteritis nodosa	1 (7)	0 (0)	1 (14)	0.466[e]
Glomerular disorder in granulomatosis with polyangiitis	1 (7)	1 (12.5)	0 (0)	1[e]
Hydronephrosis with ureteropelvic junction obstruction	1 (7)	0 (0)	1 (0)	0.466[e]
Other chronic kidney disease	1 (7)	0 (0)	1 (14)	0.466[e]
Polycystic kidney disease, unspecified	1 (7)	1 (12.5)	0 (0)	1[e]
Median (IQR)				
Follow-up time, months	37 (9-50)	29 (9-40)	41 (24-70)	0.189[c]
PRA I >0, %[b]	52 (20-64)	52 (36-62)	36 (22-50)	NA[f]
PRA II >0, %[b]	17 (17-58)	17 (17-17)[g]	99 (99-99)[h]	NA[f]
Cold ischemia, hours	21 (19-22)	22 (19-23)	21 (19-22)	0.491[f]
HLA eplet mismatch sum, n	28 (17-46)	38 (23-49)	27 (14-33)	0.182[c]
HLA I eplet mismatch sum, n	9 (7-13)	12 (7-19)	9 (8-11)	0.521[c]
HLA II eplet mismatch sum, n	22 (8-28)	23 (14-30)	8 (7-25)	0.269[c]

HLA, human leukocyte antigen; IgA, Immunoglobulin A; IQR, interquartile range; PRA, panel-reactive antibody.
[a]The significance of variation was calculated between rejection and non-rejection group of patients with
rs7542235 GG-genotype.
[b]The medians of PRA values are calculated only from patients with PRAI >0 and PRAII >0.
[c]The Mann–Whitney U-test.
[d]The Pearson chi-square test.
[e]Fisher's exact test.
[f]The significance of variation was not analyzed due to the low frequency count.
[g]n = 2
[h]n = 1
[f]The Student's t-test.
478

479   **Table 3. Detailed description of serum samples.**

Sample ID (pseudonymized)	Sample number in the Figure 4	Pre-tx sample	Post-tx sample	The region for homozygous deletion according to MLPA/WGS	The region for heterozygous deletion according to MLPA/WGS	Rejection*
ABGR4XFUNH	1	x		CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		0
ABGR4XFUNH	2		x	CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		0
BCZORKR4A3	3	x		CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		0
DGYMLR5QCF	4	x		no deletion control sample		0
EN257NXZIH	5	x		CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		0
NQZTUVJ6JA	6	x		CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		0
3RVWTIW47P	7	x		CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		1
3RVWTIW47P	8		x	CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		1
ADCKGCMCUK	9	x		CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		1
ADCKGCMCUK	10		x	CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		1
JUIHLJXRHX	11	x		CFHR1 (exons 1⬚6)	CFHR3 (exons 1⬚6), CFHR4 (exons 1⬚10)	1
JUIHLJXRHX	12		x	CFHR1 (exons 1⬚6)	CFHR3 (exons 1⬚6), CFHR4 (exons 1⬚10)	1
QDM2EBUWCF	13	x		CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		1
QDM2EBUWCF	14		x	CFHR3 (exons 1⬚6), CFHR1 (exons 1⬚6)		1
V53C3LDXJW	15	x		CFHR3 (exon 6), CFHR1 (exons 1⬚6)	CFHR3 (exons 1⬚4), CFHR4 (exons 1⬚6)	1
V53C3LDXJW	16		x	CFHR3 (exon 6), CFHR1 (exons 1⬚6)	CFHR3 (exons 1⬚4), CFHR4 (exons 1⬚6)	1

480   CFHR, complement factor H related; MLPA, multiplex ligation-dependent probe amplification; WGS, whole
481   genome sequencing; *Acute rejection status 0 = no rejection, 1 = rejection

483   **Table 4. eQTL associations of *CFHR3⬚1* deletion tagging variant rs7542235.**

FIVEx

Gene	Tissue	Chromosome	Assessed allele	Other allele	Effect size	P-value
CFHR1	blood vessel	1	G	A	-0.48	7.59×10^{-06}
CFHR1	kidney	1	G	A	-1.68	0.00
CFHR1	blood vessel	1	G	A	-0.43	0.02
CFHR1	blood vessel	1	G	A	-0.08	0.35
CFHR3	blood vessel	1	G	A	-0.92	1.17×10^{-23}
CFHR3	blood vessel	1	G	A	-0.78	1.91×10^{-16}
CFHR3	blood vessel	1	G	A	-0.96	4.17×10^{-11}
CFHR3	kidney	1	G	A	-1.64	0.00
CFHR4	kidney	1	G	A	-0.98	0.02

eQTLGen Consortium

Gene	Tissue	Chromosome	Assessed allele	Other allele	Z-score	P-value
CFH	Blood	1	G	A	10.05	8.88×10^{-24}

Human Kidney eQTL Atlas

Gene	Tissue	Chromosome	Assessed allele	Other allele	Beta*	P-value
CFHR1	kidney tubule	1	G	A	-0.77	2.73×10^{-58}
CFHR3	kidney tubule	1	G	A	-0.33	4.01×10^{-10}

484   *Effect size (Beta) is reported with respect to the alternate allele

487 **Table 5. pQTL associations of *CFHR3⬚1* deletion tagging variant rs7542235 in Olink and SomaScan data.**

Olink (n = 1225)

Gene	Chromosome	Assessed allele	Other allele	Beta	P-value	FDR
CFH	1	G	A	0.415	2.335×10^{-12}	5.794×10^{-08}
CFHR2	1	G	A	0.375	2.542×10^{-10}	3.154×10^{-06}
CFHR5	1	G	A	0.329	2.970×10^{-08}	2.457×10^{-04}

SomaScan (n = 865)

Gene	Chromosome	Assessed allele	Other allele	Beta	P-value	FDR
AKR1B10	1	G	A	-0.870	6.008×10^{-37}	2.171×10^{-32}
CFH	1	G	A	0.366	1.813×10^{-07}	0.001
CFHR1	1	G	A	-0.821	1.053×10^{-33}	3.803×10^{-29}
CFHR5	1	G	A	0.402	9.306×10^{-09}	3.955×10^{-05}
DYNLT3	1	G	A	0.365	1.946×10^{-07}	0.001
F13B	1	G	A	0.434	5.307×10^{-10}	2.950×10^{-06}
GLT8D1	1	G	A	-0.408	5.618×10^{-09}	2.706×10^{-05}
KIRREL1	1	G	A	0.353	4.784×10^{-07}	0.002
LRP1B	1	G	A	-0.344	9.862×10^{-07}	0.003
MAN1B1	1	G	A	0.445	1.969×10^{-10}	1.294×10^{-06}
MYCT1	1	G	A	-0.327	3.344×10^{-06}	0.010
NAGLU	1	G	A	-0.627	1.114×10^{-19}	1.341×10^{-15}
NDUFS4	1	G	A	0.643	1.077×10^{-20}	1.556×10^{-16}
OTOR	1	G	A	-0.406	6.562×10^{-09}	2.964×10^{-05}
PRLR	1	G	A	-1.029	9.618×10^{-55}	6.950×10^{-50}
RIPPLY3	1	G	A	0.610	1.142×10^{-18}	1.179×10^{-14}
RPS6KA1	1	G	A	-0.417	2.676×10^{-09}	1.381×10^{-05}
SCRN3	1	G	A	0.553	1.627×10^{-15}	1.307×10^{-11}
TST	1	G	A	0.479	6.902×10^{-12}	4.988×10^{-08}
UGT2B15	1	G	A	0.555	1.254×10^{-15}	1.132×10^{-11}
ULBP2	1	G	A	0.439	3.291×10^{-10}	1.981×10^{-06}
ZDHHC4	1	G	A	0.326	3.497×10^{-06}	0.010

FDR, false detection rate

FIGURE LEGENDS

Figure 1. MLPA results for rs7542235 GG genotype patients with rejection (A) and without

rejection (B). Deletion type 1 indicates homozygous deletion at *CFHR3* exons (ex) 1⎕6 and

CFHR1 ex 1⎕6. Deletion type 2 indicates homozygous deletion at *CFHR1* ex 2⎕6 and

heterozygous deletions at *CFHR3* ex 1⎕6 and *CFHR4* ex 1⎕10. Deletion type 3 indicates

homozygous deletion at *CFHR3* ex 6 and *CFHR1* ex 1⎕6 and heterozygous deletions at *CFHR3*

ex 1⎕4 and *CFHR4* ex 1⎕6. CFHR, complement factor H related; MLPA, multiplex ligation-

dependent probe amplification.

Figure 2. MLPA results for rs7542235 AA genotype (A) and AG genotype (B) patients.

Patients with rs7542235 AA genotype had normal genotype without deletions. Patients with

rs7542235 AG genotype carried a heterozygous deletion covering *CFHR3* ex 1⎕6 and *CFHR1*

ex 1⎕6. CFHR, complement factor H related; MLPA, multiplex ligation-dependent probe

amplification.

Figure 3. Detailed example of MLPA and WGS results for Deletion type 3. Patient with

homozygous deletion covering *CFHR3* exon 6 and *CFHR1* exons 1⎕6, and heterozygous

deletions covering *CFHR3* exons 1⎕4 and *CFHR4* exons 1⎕4. A) *CFH/CFHR* gene locus, exons

and deletions of patient V53C3LDXJW. B) MLPA result for the *CFH/CFHR* locus. The deletion

is denoted by the red spots below the deletion cut-off line (red) in the ratio chart. The red

line represents the 0.7 ratios, and the blue line represents the 1.3 ratios. Above the blue line

are the genes covered by the SALSA MLPA probemix, P236 *CFH* Region B1. C) Visualization

of homozygous deletion in WGS data at the beginning of *CFHR3* gene exon 6. Control

sample without deletion above, the patient sample below. D) Visualization of heterozygous

deletion in WGS data at the end of *CFHR4* gene. The coverage (gray) decreases half in size at

the heterozygous deletion region. CFH, complement factor H; CFHR, complement factor H

related; MLPA, multiplex ligation-dependent probe amplification; WGS, whole genome

sequencing.

Figure 4. Western blot analyses of CFH, CFHR1 and CFHR2 protein expression. The detailed

information for each serum sample is described in Table 3. The sample number 4 (control)

and normal human serum (NHS, also control) have normal expression of CFHR1. The other

samples are individuals with homozygous deletion of *CFHR1* gene. CFH, complement factor

H; CFHR, complement factor H related.